Literature DB >> 20920036

A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity.

R A Cantrell1, C I Alatorre, E J Davis, V Zarotsky, E Le Nestour, G Cuyún Carter, I Goetz, R Paczkowski, J Sierra-Johnson.   

Abstract

The response to treatment for type 2 diabetes typically varies among individuals within a study population. This variation is known as heterogeneity of treatment response. We conducted a comprehensive literature review to identify factors that account for heterogeneity of treatment response in patients treated for type 2 diabetes. Three databases (PubMed, EMBASE and Cochrane Library) were searched for articles published in the last 10 years describing investigations of factors associated with treatment response and outcomes among people with type 2 diabetes receiving pharmacological treatment. Of the 43 articles extracted and summarized, 35 (81%) discussed clinical factors, 31 (72%) described sociodemographic factors and 17 (40%) reported on comorbidity or behavioural factors. Clinical factors identified included baseline glycated hemoglobin A1c or fasting plasma glucose (FPG) levels, insulin response or sensitivity, C-peptide, body composition, adipose tissue proteins, lipid profile, plasma albumin levels and duration of disease or insulin treatment. Other factors identified included age, sex, race, socioeconomic status and comorbidities. This review identified the following research gaps: use of multiple definitions for response, few patient-reported measures and lack of evidence regarding whether factors were associated with treatment response for only specific medications or across pharmacological therapies. Furthermore, identification of factors associated with type 2 diabetes treatment response was generally a secondary objective in the research reviewed. Understanding which patient subgroups are more likely to respond to treatment and identifying factors associated with response may result in targeted treatment decisions and alter the interpretation of efficacy or effectiveness of results. In conclusion, accounting for these factors in clinical trials and when making clinical treatment decisions may improve therapy selection and individual patient outcomes.
© 2010 Eli Lilly and Company.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920036     DOI: 10.1111/j.1463-1326.2010.01248.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  16 in total

1.  Health technology assessment with risk aversion in health.

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  J Health Econ       Date:  2020-06-06       Impact factor: 3.883

2.  Heterogeneity of response to biologic treatment: perspective for psoriasis.

Authors:  Emily Edson-Heredia; Kimberly L Sterling; Carlos I Alatorre; Gebra Cuyun Carter; Rosirene Paczkowski; Victoria Zarotsky; Tomoko Maeda-Chubachi
Journal:  J Invest Dermatol       Date:  2013-08-06       Impact factor: 8.551

3.  Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.

Authors:  Funda Bulut; Deniz Erol; Halit Elyas; Halil Doğan; Fethi Ahmet Ozdemir; Lezan Keskin
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

4.  Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm.

Authors:  Dana S Hardin; Rachelle D Rohwer; Bradley H Curtis; Anthony Zagar; Lei Chen; Kristina S Boye; Honghua H Jiang; Ilya A Lipkovich
Journal:  J Diabetes Sci Technol       Date:  2013-03-01

5.  Empowering Patients and Providers With More and Better Data: Innovative Concepts in Type 2 Diabetes Management.

Authors:  Cody J Lensing; Stephen R Garth; Ben W Ehlert; Jessyca M Duerr; Craig D Wagner; Kevin A Kapov; Jared P Jones; Shane R Hoversten
Journal:  Diabetes Spectr       Date:  2019-11

6.  Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients.

Authors:  Feng-Fei Li; Bing-Li Liu; Guo-Ping Yin; Dan-Feng Zhang; Xiao-Fang Zhai; Mao-Yuan Chen; Xiao-Fei Su; Jin-Dan Wu; Lei Ye; Jian-Hua Ma
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

7.  Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.

Authors:  Ildiko Lingvay; Stewart Harris; Elmar Jaeckel; Keval Chandarana; Mattis F Ranthe; Esteban Jódar
Journal:  Diabetes Obes Metab       Date:  2017-07-31       Impact factor: 6.577

8.  Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens.

Authors:  Li Xin Shi; Peng Fei Li; Jia Ning Hou
Journal:  Diabetes Ther       Date:  2017-06-30       Impact factor: 2.945

9.  Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.

Authors:  John M Dennis; William E Henley; Michael N Weedon; Mike Lonergan; Lauren R Rodgers; Angus G Jones; William T Hamilton; Naveed Sattar; Salim Janmohamed; Rury R Holman; Ewan R Pearson; Beverley M Shields; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2018-08-02       Impact factor: 19.112

10.  Type 2 diabetes: a cohort study of treatment, ethnic and social group influences on glycated haemoglobin.

Authors:  Gareth D James; Peter Baker; Ellena Badrick; Rohini Mathur; Sally Hull; John Robson
Journal:  BMJ Open       Date:  2012-10-18       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.